The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors
NCT02449564
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
sirolimus
Sponsor
Samsung Medical Center